SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX
Clinical trials for SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX explained in plain language.
Never miss a new study
Get alerted when new SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX trials appear
Sign up with your email to follow new studies for SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New study aims to tailor throat cancer treatment, reduce side effects
Disease control Recruiting nowThis study tests a personalized approach to treating p16-positive oropharyngeal cancer (a type of throat cancer linked to HPV). The goal is to use less intense treatment—either surgery with tailored follow-up or customized chemoradiation—to maintain high cure rates while reducing…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated May 26, 2026 10:05 UTC
-
Blood test guides safer radiation for throat cancer
Disease control Recruiting nowThis study is for people with HPV-related throat cancer who need radiation therapy. Researchers are using a blood test that tracks tumor DNA to decide if a lower dose of radiation can be safely given to the neck. The goal is to keep the cancer under control while reducing side ef…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX
Phase: PHASE2 • Sponsor: University of Virginia • Aim: Disease control
Last updated May 26, 2026 10:02 UTC
-
Less radiation, same protection: new trial for head and neck cancer
Disease control Recruiting nowThis study tests whether giving less radiation after surgery for head and neck cancer can reduce long-term side effects, like trouble swallowing, without increasing the chance of cancer coming back. About 508 adults with certain types of head and neck cancer will be randomly assi…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX
Phase: PHASE2, PHASE3 • Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Disease control
Last updated May 26, 2026 09:59 UTC